210 related articles for article (PubMed ID: 38350611)
1. miR-1202 acts as anti-oncomiR in myeloid leukaemia by down-modulating GATA-1
Sessa R; Trombetti S; Bianco AL; Amendola G; Catapano R; Cesaro E; Petruzziello F; D'Armiento M; Maruotti GM; Menna G; Izzo P; Grosso M
Open Biol; 2024 Feb; 14(2):230319. PubMed ID: 38350611
[TBL] [Abstract][Full Text] [Related]
2. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C; Cruz Hernandez D; Vyas P
IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
[TBL] [Abstract][Full Text] [Related]
3. Haematopoietic development and leukaemia in Down syndrome.
Roberts I; Izraeli S
Br J Haematol; 2014 Dec; 167(5):587-99. PubMed ID: 25155832
[TBL] [Abstract][Full Text] [Related]
4. PRAME immunohistochemical staining in transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome.
Chisholm KM; Rivetta CV; Heerema-McKenney A
Ann Clin Lab Sci; 2015; 45(2):121-7. PubMed ID: 25887863
[TBL] [Abstract][Full Text] [Related]
5. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Leukemogenic Potential of GATA-1
Trombetti S; Sessa R; Catapano R; Rinaldi L; Lo Bianco A; Feliciello A; Izzo P; Grosso M
Antioxidants (Basel); 2021 Oct; 10(10):. PubMed ID: 34679737
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
Watanabe K
Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
[TBL] [Abstract][Full Text] [Related]
8. [Myeloid proliferations related to Down syndrome].
Hasegawa D
Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
[TBL] [Abstract][Full Text] [Related]
9. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
[TBL] [Abstract][Full Text] [Related]
10. GATA-1 isoforms differently contribute to the production and compartmentation of reactive oxygen species in the myeloid leukemia cell line K562.
Riccio P; Sessa R; de Nicola S; Petruzziello F; Trombetti S; Menna G; Pepe G; Maddalena P; Izzo P; Grosso M
J Cell Physiol; 2019 Nov; 234(11):20829-20846. PubMed ID: 31049966
[TBL] [Abstract][Full Text] [Related]
11. A Case of Novel GATA-1 Mutation-positive Transient Abnormal Myelopoiesis With Life-threatening Complications in a Neonate With Down Syndrome.
Sah RR; Ray S; Bhatia P; Dhir SK; Totadri S; Kumar N; Kumar P
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e292-e295. PubMed ID: 31876781
[TBL] [Abstract][Full Text] [Related]
12. Transcription factor GATA-1 and Down syndrome leukemogenesis.
Muntean AG; Ge Y; Taub JW; Crispino JD
Leuk Lymphoma; 2006 Jun; 47(6):986-97. PubMed ID: 16840187
[TBL] [Abstract][Full Text] [Related]
13. Mutation characterization in the GATA-1 gene in patients with Down's Syndrome diagnosed with transient abnormal myelopoiesis or acute megakaryoblastic leukemia.
Mansini AP; Rubio PL; Rossi JG; Gallego MS; Medina A; Zubizarreta PA; Felice MS; Alonso CN
Arch Argent Pediatr; 2013 Dec; 111(6):532-6. PubMed ID: 24196768
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome.
Toki T; Kanezaki R; Kobayashi E; Kaneko H; Suzuki M; Wang R; Terui K; Kanegane H; Maeda M; Endo M; Mizuochi T; Adachi S; Hayashi Y; Yamamoto M; Shimizu R; Ito E
Blood; 2013 Apr; 121(16):3181-4. PubMed ID: 23440243
[TBL] [Abstract][Full Text] [Related]
15. Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome.
Saida S; Watanabe K; Sato-Otsubo A; Terui K; Yoshida K; Okuno Y; Toki T; Wang R; Shiraishi Y; Miyano S; Kato I; Morishima T; Fujino H; Umeda K; Hiramatsu H; Adachi S; Ito E; Ogawa S; Ito M; Nakahata T; Heike T
Blood; 2013 May; 121(21):4377-87. PubMed ID: 23482930
[TBL] [Abstract][Full Text] [Related]
16. Over-Expressed GATA-1
Trombetti S; Iaccarino N; Riccio P; Sessa R; Catapano R; Salvatore M; Luka S; de Nicola S; Izzo P; Roperto S; Maddalena P; Randazzo A; Grosso M
Antioxidants (Basel); 2023 Feb; 12(3):. PubMed ID: 36978786
[TBL] [Abstract][Full Text] [Related]
17. Bullous eruptions in transient abnormal myelopoiesis with normal phenotype.
Shivamallappa MD; Mullins A; Browning Carmo K
BMJ Case Rep; 2023 Apr; 16(4):. PubMed ID: 37028822
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
Labuhn M; Perkins K; Matzk S; Varghese L; Garnett C; Papaemmanuil E; Metzner M; Kennedy A; Amstislavskiy V; Risch T; Bhayadia R; Samulowski D; Hernandez DC; Stoilova B; Iotchkova V; Oppermann U; Scheer C; Yoshida K; Schwarzer A; Taub JW; Crispino JD; Weiss MJ; Hayashi Y; Taga T; Ito E; Ogawa S; Reinhardt D; Yaspo ML; Campbell PJ; Roberts I; Constantinescu SN; Vyas P; Heckl D; Klusmann JH
Cancer Cell; 2019 Aug; 36(2):123-138.e10. PubMed ID: 31303423
[TBL] [Abstract][Full Text] [Related]
20. Myeloid Proliferations Associated with Down Syndrome: Clinicopathologic Characteristics of Forty Cases from Five Large Academic Institutions.
van den Akker TA; Liu YC; Liu H; Chapman J; Levine JM; Weinberg OK; Geyer JT
Pathobiology; 2024; 91(1):89-98. PubMed ID: 36996802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
